The notable peptide vaccines that have undergone phase I/II/III clinical trials include HER-2/neu immunodominant peptide (lung, breast, or ovarian cancer) [69–71], Mucin-1 (MUC-1, Stimuvax), peptide (breast or colon cancer) [72, 73], Carcinoembryonic antigen (colorectal, gastric, breast, pancreatic and non-small-cell lung cancers) [74, 75], Prostate-specific membrane antigen (prostate cancer) [76–78], HPV-16 E7 peptide (cervical cancer) [79], Ras oncoprotein peptide (colorectal and pancreatic carcinomas) [80–82], and Melanoma antigens (Melanoma) [62, 68, 83–85]. The gene discussed is ERBB2; the disease is colonic neoplasm.